DE | EN
 
 
 
 
 
 
 
   
 

24: The neuroscience and phenomenology of sensory loss

Alper G, Narayanan V (2003) Friedreich’s ataxia. Pediatr Neurol 28 (5): 335-341

Camdessanche JP, Antoine JC, Honnorat J, Vial C, Petiot P, Convers P, Michel D (2002) Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain 125(1): 166-175

Cole J (1991) Pride and a Daily Marathon. Duckworth, London (reprinted by The MIT Press, London and Cambridge, MA, 1995)

Cole J, Gallagher S, McNeill D (2002) Gesture following deafferentation: A phenomenologically informed experimental study. Phenomenology and the Cognitive Sciences 1(1): 49-67

Cole JD, Sedgwick EM (1992) The perceptions of force and of movement in a man without large myelinated sensory afferents below the neck. J Physiol 449: 503-515

Comi G, Roveri L, Swan A et al (2002) for the Inflammatory Neuropathy Cause and Treatment Group. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 249(10): 1370-1377

Fleury M, Bard C, Teasdale N, Paillard J, Cole J, Lajoie Y, Lamarre Y (1995) Weight judgment. The discrimination capacity of a deafferented subject. Brain 118: 1149-1156

Font J, Ramos-Casals M, de la Red G, Pou A, Casanova A, Garcia-Carrasco M, Cervera R, Molina JA, Valls J, Bove A et al (2003) Pure sensory neuropathy in primary Sjogren’s syndrome. Long-term prospective follow-up and review of the literature. J Rheumatol 30(7): 1552-1557

Forget R, Lamarre Y (1987) Rapid elbow flexion in the absence of proprioceptive and cutaneous feedback. Human Neurobiol 6: 27-37

Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, Stewart DJ (1992) Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10 (5): 795-803

Koenig M (2003) Rare forms of autosomal recessive neurodegenerative ataxia. Semin Pediatr Neurol 10(3): 183-192

Lucchinetti CF, Kimmel DW, Lennon VA (1998) Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 50: 652-657

McNeill D (2005) Gesture and Thought. University of Chicago Press, Chicago

Miall RC, Cole JD (2007) Evidence for stronger visuo-motor than visuo-proprioceptive conflict during mirror drawing performed by a deafferented subject and control subjects. Exp Brain Res 176(3): 432-439

Nowak D, Glasauer S, Hermsdorfer J (2004) How predictive is grip force control in the complete absence of somatosensory feedback? Brain 127: 1-11

O’Leary CP, Willison HJ (1997) Autoimmune ataxic neuropathies (sensory ganglionopathies). Curr Opin Neurol 10(5): 366-370

Phillips C (1985) Movements of the hand. Liverpool University Press, Liverpool

Rolke R, Magerl W, Andrews Campbell K, Schalber C, Caspari S, Birklein F, Treede RD (2006) Quantitative sensory testing: a comprehensive protocol for clinical trials. Eur J Pain 10: 77-86

Rothwell JC, Traub MM, Day BL, Obeso JA, Marsden CD, Thomas PK (1982) Manual motor performance in a deafferented man. Brain 105: 515-542

Schaumburg HH, Kaplan J, Windebank A, Vick N, Rasmus S, Pleasure Brown MJ (1983) Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med 309(8): 445-448

Shy ME, Frohman EM, So YT, Arezzo JC, Cornblath DR, Giuliani MJ, Kincald JC, Ochoa JL, Parry GJ, Weimer LH (2003) Quantitative sensory testing. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 60: 898-904

Sillevis Smitt P, Grefkens J, de Leeuw B, van den Bent M, van Putten W, Hooijkaas H, Vecht C (2002) Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/ sensory neuronopathy. J Neurol 249(6): 745-753

Sterman AB, Schaumburg HH, Asbury AK (1980) The acute sensory neuronopathy syndrome; a distinct clinical entity. Ann Neurol 7(4): 354-358

van der Bent MJ, van Putten WL, Hilkens PH, de Wit R, van der Burg ME (2002) Re-treatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity. Eur J Cancer 38(3): 387-391